Human macrophages make two interferons early in tuberculosis

Tuberculosis remains a major infectious disease and researchers are still piecing together how the immune system responds to Mycobacterium tuberculosis (Mtb). One part of that response involves type I interferons (IFNs), signaling proteins known to shape TB disease processes. For a long time it was assumed that macrophages — the immune cells that engulf bacteria — produce the two main type I IFN proteins, IFNα and IFNβ, during Mtb infection. But curiously, direct measurements of those proteins in human macrophages were not on record. In new work led by Gina Leisching, scientists set out to fill that gap. They used primary human monocyte-derived macrophages (MDMs) and infected them with both a virulent strain of Mtb (H37Rv) and an attenuated laboratory strain (H37Ra) to see whether the cells actually released IFNα and IFNβ protein. The study focused on measuring protein levels rather than indirectly inferring production from gene activity, and it tracked the timing of secretion over several days post-infection.

The core advance of the study was direct protein quantification in MDMs following infection with Mtb strains H37Rv and H37Ra. By looking at post-infection time points, the researchers detected both IFNα and IFNβ protein in the culture medium as early as 48 h post-infection. Those measurable levels did not disappear quickly: the proteins remained detectable at 120 h post-infection. Detecting both IFNα and IFNβ in primary human macrophages infected with both a virulent and an attenuated strain challenges the idea that macrophage secretion of type I IFNs might be rare or delayed. The use of primary human monocyte-derived macrophages (MDMs) is important because it avoids some uncertainties that can arise when using cell lines, and the comparison between H37Rv and H37Ra shows the phenomenon occurs with both virulent and attenuated Mtb strains.

These results matter because they change how scientists should think about the timing of immune signals during TB infection. If macrophages begin secreting IFNα and IFNβ within 48 h and continue for days, experiments that sample only early or very late time points could miss important biology. The findings therefore imply that timing is critical in experimental design when studying type I IFNs in TB. Beyond experimental setups, the observation provides a foundation for new studies probing how IFNα and IFNβ influence the interaction between host and pathogen during tuberculosis. While this work does not yet define whether these interferons help or harm the host, it clarifies that primary human macrophages are a source of both proteins after Mtb infection and sets the stage for follow-up research to map their precise roles in disease progression and immune control.